7 completed, 4 recruiting, 4 terminated, 1 enrolling by invitation. 9 Phase 2, 4 Phase 4, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Recruiting 3, Completed 2, Terminated 2, Enrolling by invitation 1, Not yet recruiting 1 |
| Phase 4 | 4 | Completed 2, Terminated 2 |
| Phase 1 | 3 | Completed 2, Recruiting 1 |
| Phase 3 | 2 | Completed 2 |
Follow Oral Vancomycin: new trials by email Literature Review of Oral Vancomycin trials Research Report on Oral Vancomycin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vancomycin Efficacy in Response to Dysbiosis in Atypical Colitis Oral Vancomycin - Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC) | Phase 2 | Not yet recruiting | Tampere University Hospital | 140 | 2026-10-01 | 2026-09-10 |
| Maternal Probiotic Intervention to Improve Gut Health-Trial II-Pakistan Oral Vancomycin, VE818, Placebo - Environmental Enteric Dysfunction (EED), Stunting | Phase 2 | Recruiting | Aga Khan University | 144 | 2025-08-30 | 2025-10-06 |
| Maternal Probiotic Intervention to Improve Gut Health - Trial II - Burkina Faso (MPIGH-II) VE818, Placebo, Oral Vancomycin - Environmental Enteric Dysfunction (EED) | Phase 2 | Recruiting | University Ghent | 144 | 2025-07-30 | 2025-11-17 |
| Maternal Probiotic Intervention to Improve Gut Health - Trial II - Bangladesh VE818, Placebo, Oral Vancomycin - Environmental Enteric Dysfunction | Phase 2 | Enrolling by invitation | International Centre for Diarrhoeal Disease Research, Bangladesh | 144 | 2025-04-20 | 2025-12-10 |
| Vancomycin in Primary Sclerosing Cholangitis in Italy Oral Vancomycin, Placebo - Primary Sclerosing Cholangitis, Liver and Intrahepatic Bile Duct Disorder | Phase 2 | Recruiting | University of Milano Bicocca | 84 | 2023-06-15 | 2025-07-25 |
| Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients FMT oral capsule, Oral Vancomycin, FMT oral placebo - Clostridium Difficile Infection Recurrence | Phase 2 | Terminated | University of Wisconsin, Madison | 3 | 2022-08-03 | 2025-01-09 |
| Oral Vancomycin Vs Placebo in the Prevention of Recurrence of Clostridioides Difficile's Infection Oral Vancomycin, Placebo - Clostridioides Difficile Infection | Phase 3 | Completed | Julia Orígüen | 24 | 2022-08-02 | 2024-12-12 |
| A Systems Biology Approach for Identification of Host and Microbial Mechanisms and Druggable Targets for the Treatment of PSC-IBD Oral Vancomycin - Inflammatory Bowel Diseases, Primary Sclerosing Cholangitis | Unknown | University Hospital Birmingham NHS Foundation Trust | 15 | 2022-02-01 | 2022-06-01 | |
| VE303 for Treatment of Hepatic Encephalopathy (HE) Placebo, VE303, oral vancomycin - Cirrhosis, Hepatic Encephalopathy | Phase 2 | Completed | Patricia Bloom | 19 | 2021-08-06 | 2025-02-07 |
| Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI) Oral Vancomycin, Placebo - Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence | Phase 4 | Terminated | University of South Florida | 26 | 2019-09-01 | 2023-04-21 |
| Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers nivolumab, tadalafil, oral vancomycin - Hepatocellular Carcinoma, Hepatocellular Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 22 | 2019-06-05 | 2026-02-23 |
| Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics Oral Vancomycin - Clostridium Difficile Infection | Phase 4 | Completed | University of Nevada, Reno | 104 | 2018-03-08 | 2023-11-28 |
| TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment Oral Vancomycin, Placebo, Toxin enzyme immunoassay - Clostridium Difficile Infection, Diarrhea | Phase 4 | Completed | Washington University School of Medicine | 15 | 2017-12-29 | 2021-07-26 |
| First-in-human Study of VE303 in Healthy Adult Volunteers VE303, Oral Vancomycin - Healthy Volunteers | Phase 1 | Completed | Vedanta Biosciences, Inc. | 39 | 2017-11-28 | 2020-01-27 |
| Oral Vancomycin for Preventing Clostridium Difficile Recurrence Oral Vancomycin, Placebo - Clostridium Difficile Infection | Phase 4 | Terminated | Rochester General Hospital | 65 | 2017-06-08 | 2021-04-26 |
| Beneficial Bacteria Treatment for Autism oral Vancomycin, MoviPrep, Prilosec - Gastrointestinal Problems, Autism Spectrum Disorders | Phase 1 / Phase 2 | Completed | Arizona State University | 18 | 2014-07-01 | 2025-09-12 |
| Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects Oral Vancomycin - Primary Sclerosing Cholangitis | Phase 3 | Completed | Stanford University | 34 | 2012-01-01 | 2018-09-21 |
| Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin Oral Vancomycin - Primary Sclerosing Cholangitis, Biliary Atresia | Phase 1 | Recruiting | Sacramento Pediatric Gastroenterology | 200 | 2010-07-01 | 2016-11-15 |
Cholangitis, Sclerosing (5) · Clostridium Infections (5) · Inflammatory Bowel Diseases (2) · Autism Spectrum Disorder (1) · Biliary Atresia (1) · Bites and Stings (1) · Carcinoma, Hepatocellular (1) · Colitis (1) · Colitis, Ulcerative (1) · Colorectal Neoplasms (1) · Diarrhea (1) · Digestive System Diseases (1) · Fibrosis (1) · Growth Disorders (1) · Hepatic Encephalopathy (1)
Aga Khan University (1) · Arizona State University (1) · International Centre for Diarrhoeal Disease Research, Bangladesh (1) · Julia Orígüen (1) · National Cancer Institute (NCI) (1) · Patricia Bloom (1) · Rochester General Hospital (1) · Sacramento Pediatric Gastroenterology (1) · Stanford University (1) · Tampere University Hospital (1) · University Ghent (1) · University Hospital Birmingham NHS Foundation Trust (1) · University of Milano Bicocca (1) · University of Nevada, Reno (1) · University of South Florida (1)
United States (10) · Bangladesh (1) · Burkina Faso (1) · Finland (1) · Italy (1) · Pakistan (1) · Spain (1) · United Kingdom (1)
Asad Ali Syed, MPH (1) · Carl Lachat, M.Eng., Ph.D. (1) · Erik Dubberke, MD, MSPH (1) · James B Adams, PhD (1) · Kenneth Cox, MD (1) · Lauren Zion, PharmD (1) · Maryrose R Laguio-Vila, MD (1) · Mindy Sampson, DO (1) · Nasia Safdar, MD, PhD (1) · Patricia Bloom, MD (1) · Tim F Greten, M.D. (1) · Yinka Davies, M.D. (1)
PMID 23054338, PMID 28122648, PMID 30967657, PMID 32633158, PMID 33087514, PMID 33441409, PMID 37709311, PMID 39673746, PMID 39969428, PMID 41513411
2025 (1), U01AI125053 (1)